Elevance Health, Inc. ELV

Currently 3 bullish, 0 bearish — stable.

Analysts are holding steady at 3 bullish to 0 bearish.

2 YouTube analysts cover Elevance Health, Inc. (ELV).

2 analysts have covered ELV so far…

Analyst opinions

StockCharts TV16d ago

BULL$ELVSwingTechnical

breakout turns resistance into support as momentum stays constructive.

ELV is compelling after breaking out and flipping resistance into support, staying constructive while momentum remains above the 21-day EMA.

ELV moved to new three-month highs, then broke above prior resistance around 380, with that level becoming support after the breakout. The bullish checklist is simple: remain above the 21-day EMA and keep momentum constructive; failure there would undermine the accumulation-phase thesis.

"June 2026: The 10 Most Important Charts to Watch"

OptionsPlay68d ago

BULL$ELV

2027 Medicare rates beat by wide margin

Elevance Health's 2027 Medicare rates came in much better than expected (roughly a 5% blended/risk-adjusted growth equating to about $13), which supports a healthier revenue outlook and recent upside in the stock.

Elevance Health's 2027 Medicare rates came in roughly 5% better than expected on a blended risk-adjusted basis, supporting a healthier revenue trajectory. The stronger-than-anticipated payer margin visibility underpins recent upside and a more constructive earnings outlook.

"Wall Street Just Forgot About a War"

OptionsPlay75d ago

BULL$ELV

Medicare improvement drives upside to mid-300s

I view Elevance Health as my top defensive healthcare pick given improving 2027 risk-adjusted Medicare payments and a path to meaningful upside from current levels into the mid-300s.

Elevance Health is the top defensive healthcare pick, supported by improving 2027 risk-adjusted Medicare payment dynamics that create a credible path to mid-300s price levels. Its defensive characteristics underpin the conviction amid broader macro uncertainty.

"Stop Buying Options. Get Paid to Wait Instead."

No official filings surfaced for ELV yet.